Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test

European Neuropsychopharmacology

Volumn 16, Issue 5, 2006, Pages 324-328

  Farzin, Davood ^a   Mansouri, Nazanin ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carbolines; Depression; Forced swim test; Harmane; Harmine; Mouse; Norharman

Indexed keywords

BENZODIAZEPINE RECEPTOR; BETA CARBOLINE; BETA CARBOLINE DERIVATIVE; FLUMAZENIL; HARMAN; HARMINE; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG RECEPTOR BINDING; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLUMAZENIL; GABA MODULATORS; HARMINE; MALE; MICE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; RESERPINE; SWIMMING; SYMPATHOLYTICS;

EID: 33745177316     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.08.005     Document Type: Article

References (52)

1. Adell A., Biggs T.A., and Myers R.D. Action of harman (1-methyl-β-carboline) on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 35 (1996) 1101-1107
2. Airaksinen M.M., and Kari I. β-carbolines, psychoactive compounds in the mammalian body: part I. Occurrence, origin and metabolism. Med. Biol. 59 (1981) 21-34
3. Allen M.S., Laloggia A.J., Dorn L.J., Martin M.J., Costantino G., Hagen T.J., Koehler K.F., Skolnick P., and Cook J.M. Predictive binding of β-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J. Med. Chem. 35 (1992) 4001-4010
4. Barbaccia M.L., Ravizza L., and Costa E. Maprotiline: an antidepressant with an unusual pharmacological profile. J. Pharmacol. Exp. Ther. 236 (1986) 307-312
5. Beck O., and Faull K.F. Concentrations of the enantiomers of 5-ydroxymethtryptoline in mammalian urin: implications for in vivo biosynthesis. Biochem. Pharmacol. 35 (1986) 2636-2639
6. Borsini F., and Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology 94 (1988) 147-160
7. Cappendijk S.L.T., Fekkes D., van Dalen A., and Pepplinkhuizen L. The acute effects of norharman on cocaine self-administration and sensorimotor function in male Wistar rats. Eur. Neuropsychopharmacol. 11 (2001) 233-239
8. Cowen P.J., Green A.R., and Nutt D.J. Ethyl beta-carboline carboxylate lowers seizure threshold and antagonizes flurazepam-induced sedation in rats. Nature 290 (1981) 54-55
9. Fernandez de Arriba A., Lizcano J.M., Balsa M.D., and Unzeta M. Inhibition of monoamine oxidase from bovine retina by β-carbolines. J. Pharm. Pharmacol. 46 (1994) 809-813
10. Fuller R.W., Wong C.J., and Hemrick-Luecke S.K. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice. Life Sci. 38 (1986) 409-412
11. Garcia-Sevilla J.A., Escriba P.V., and Guimon J. Imidazoline receptors and human brain disorders. Ann. N.Y. Acad. Sci. 881 (1999) 392-409
12. Hoffman E.J., and Warren E.W. Flumazenil: a benzodiazepine antagonist. Clin. Pharm. 12 (1993) 641-656
13. Hollinshead S.P., Trudell M.L., Skolnick P., and Cook J.M. Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-(4-methoxy methyl)-β-carboline-3-carboxylic acid ethyl ester. J. Med. Chem. 33 (1990) 1062-1069
14. Husbands S.M., Glennon R.A., Gorgerat S., Gough R., Tyacke R., Crosby J., Nutt D.J., Lewis J.W., and Hudson A.L. β-carboline binding to imidazoline receptors. Drug Alcohol Depend. 64 (2001) 203-208
15. Jackson H.C., Mirza N.R., Nutt D.J., Jordan S., and Handley S.L. Antidepressant-like effects of the I2-ligands idazoxan and 2-BFI in the rat porsolt test. Eur. Neuropsychopharmacol. 6 Suppl 3 (1996) 54
16. Kleven M.S., and Woolverton W.L. Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys. Drug Alcohol Depend. 31 (1993) 149-158
17. Komulainen H., Tuomisto J., Airaksinen M.M., Kari I., Peura P., and Pollari L. In vitro inhibition of serotonin, dopamine and noradrenaline uptake in rat brain synaptosomes. Acta Pharm. Toxicol. 46 (1980) 299-307
18. 3H]imipramine recognition site. Eur. J. Pharmacol. 98 (1984) 153-154
19. Li W.K. Extraction of alkaloids from Peganum harmala L. and study on their antihydatid chemical composition. J. Lanzhou Med. Coll. 22 (1996) 16-18
20. Loew G.H., Nienow J., Lawson J.A., Toll L., and Uyeno E.T. Theoretical structure-activity studies of β-carboline analogs. Requirements for benzodiazepine receptor affinity and antagonist activity. Mol. Pharmacol. 28 (1985) 17-31
21. Lutes J., Lorden J.F., Beales M., and Lotmans G.A. Tolerance to the tremorogenic effects of harmaline: evidence for altered olivo-cerebellar function. Neuropharmacology 27 (1988) 849-855
22. Maes M., and Meltzer H.Y. The serotonin hypothesis of major depression. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 933-944
23. Montecrieff J. Determination of pharmacological levels of harmane, harmine and harmaline in mammalian brain tissue, cerebrospinal fluid and plasma by high-performance liquid chromatography with fluorimetric detection. J. Chromatogr. 496 (1989) 269-278
24. Muller W.E., Fehske K.J., Borbe H.O., Wollert U., Nanz C., and Rommelspacher H. On the neuropharmacology of harmane and other β-carbolines. Pharmacol. Biochem. Behav. 14 (1981) 693-699
25. Nishigata H., Yoshida D., and Matsumoto T. Determination of the yield of norharman and harman in the pyrolytic products of proteins. Agric. Biol. Chem. 44 (1980) 209-211
26. 3H]citalopram. Pharmacol. Toxicol. 80 (1997) 122-126
27. 3H]β-carboline) in the rat brain. Eur. J. Pharmacol. 147 (1988) 163-173
28. Piletz J.E., Halaris A., and Ernsberger P. Psychopharmacology of imidazoline and α2-adrenergic receptors: implications for depression. Crit. Rev. Neurobiol. 9 (1994) 29-66
29. Piletz J.E., Zhu H., Ordway G., Stockmeier C., Dilly G., Reis D., and Halaris A. Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. Biol. Psychiatry 48 (2000) 910-919
30. Pimpinella G., and Palmery M. Interaction of β-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci. Lett. 189 (1995) 121-124
31. Poindexter E.H., and Carpenter R.D. The isolation of harmane and norharmane from tobacco and cigarette smoke. Phytochemistry 1 (1962) 215-221
32. Porsolt R.D., Bertin A., and Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. 229 (1977) 327-336
33. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 (1978) 379-391
34. Prado de Carvalho L., Grecksch G., Chapouthier G., and Rossier J. Anxiogenic and non-anxiogenic benzodiazepine antagonists. Nature 301 (1983) 64-66
35. Randrup A., and Braestrup C. Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression. Psychopharmacology 53 (1977) 309-314
36. Prange A. The pharmacology and biochemistry of depression. Dis. Nerv. Syst. 25 (1964) 217-221
37. Rommelspacher H., Nanz C., Borbe H.O., Fehske K.J., Muller W.E., and Wollert U. Benzodiazepine antagonism by harmane and other beta-carbolines in vitro and in vivo. Eur. J. Pharmacol. 70 (1981) 409-416
38. Rommelspacher H., Bruning G., Susilo R., Nick M., and Hill R. Pharmacology of harmalan (1-methyl-3,4-dihydro-β-carboline). Eur. J. Pharmacol. 109 (1985) 363-371
39. Rommelspacher H., May T., and Susilo R. β-Carbolines and tetrahydroisoquinolines: detection and function in mammals. Planta Med. 57 (1991) S85-S92
40. Rommelspacher H., May T., and Salewski B. Harman (1-methyl-β-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur. J. Pharmacol. 252 (1994) 51-59
41. Rommelspacher H., Meier-Henco M., Smolka M., and Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol. 44 (2002) 115-125
42. Ruiz-Durántez E., Ruiz-Ortega J.Á., Pineda J., and Ugedo L. Stimulatory effect of harmane and other β-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci. Lett. 308 (2001) 197-200
43. Sällström-Baum S., Hill R., and Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur. J. Pharmacol. 314 (1996) 75-82
44. 2-imidazoline receptors, alpha 2-adrenoceptors and monoamine oxidase B in brains of suicide victims. Neurochem. Int. 30 (1997) 63-72
45. Schatzberg A.F., and Schildkraut J.J. Recent studies on norepinephrine systems in mood disorders. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 911-920
46. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122 (1965) 509-522
47. Schouten M.J., and Bruinvels J. Endogenously formed norharman (β-carboline) in platelet rich plasma obtained from porphyric rats. Pharmacol. Biochem. Behav. 24 (1986) 1219-1223
48. Tella S.R. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacol. Biochem. Behav. 51 (1995) 687-692
49. Tse S.Y.H., Mak I.T., and Dickens B.F. Antioxidative properties of harmane and β-carboline alkaloids. Biochem. Pharmacol. 42 (1991) 459-464
50. Wang X., Wang H., and He A. Study on the antitumor effect of total harmala. J. Chin. Med. Univ. 25 (1996) 240-242
51. Zarrindast M.R., and Minaian A. Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice. Gen. Pharmacol. 22 (1991) 1017-1021
52. Zhu H., Paul I.A., McNamara M., Redmond A., Nowak G., and Piletz J.E. Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. Neurochem. Int. 30 (1997) 101-107